Stonepine Capital Management LLC Sells 539,256 Shares of Alimera Sciences, Inc. (NASDAQ:ALIM)

Stonepine Capital Management LLC lessened its position in shares of Alimera Sciences, Inc. (NASDAQ:ALIM) by 13.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,511,816 shares of the biopharmaceutical company’s stock after selling 539,256 shares during the quarter. Alimera Sciences makes up about 17.8% of Stonepine Capital Management LLC’s holdings, making the stock its 2nd largest position. Stonepine Capital Management LLC owned about 6.70% of Alimera Sciences worth $19,526,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Deltec Asset Management LLC purchased a new position in Alimera Sciences during the 2nd quarter valued at about $690,000. Vanguard Group Inc. grew its position in shares of Alimera Sciences by 61.1% in the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after purchasing an additional 396,506 shares during the last quarter. Ancora Advisors LLC purchased a new position in shares of Alimera Sciences during the 1st quarter worth approximately $915,000. Fifth Lane Capital LP acquired a new position in shares of Alimera Sciences during the 1st quarter worth approximately $83,000. Finally, Glazer Capital LLC purchased a new stake in Alimera Sciences in the 2nd quarter valued at approximately $3,067,000. Institutional investors and hedge funds own 99.83% of the company’s stock.

Alimera Sciences Price Performance

ALIM stock opened at $5.54 on Tuesday. The stock has a market capitalization of $290.24 million, a price-to-earnings ratio of -3.53 and a beta of 1.25. The company has a quick ratio of 2.62, a current ratio of 2.79 and a debt-to-equity ratio of 1.80. Alimera Sciences, Inc. has a 52-week low of $2.61 and a 52-week high of $5.65. The stock’s fifty day simple moving average is $5.55 and its 200-day simple moving average is $4.51.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Alimera Sciences had a negative return on equity of 33.70% and a negative net margin of 14.74%. The business had revenue of $27.00 million during the quarter, compared to analyst estimates of $25.76 million. Equities research analysts expect that Alimera Sciences, Inc. will post -0.13 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Maxim Group reissued a “hold” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. Alliance Global Partners reiterated a “neutral” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. StockNews.com assumed coverage on shares of Alimera Sciences in a report on Monday. They issued a “hold” rating on the stock. Finally, HC Wainwright downgraded shares of Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 price target for the company. in a report on Tuesday, June 25th.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).